S045 Advanced Therapeutics for Complex Dermatologic Disease
DESCRIPTION
The skin is a window into the inner workings of the immune system and the rest of the body. As dermatologists, we play a critical role in diagnosis and management, but often require the help of other specialties to treat complex disease. In this session, we hope to demystify the systemic therapeutics that are often used in treatment of complex skin disease, and in areas where appropriate, will demonstrate how dermatologists can reclaim the management of systemic disease.
We will also highlight research on new adverse effects for systemic medications, as well as novel treatment paradigms in our specialty.
LEARNING OBJECTIVES
Develop treatment algorithms for complex medical dermatologic conditions: connective tissue diseases, hidradenitis suppurativa, GVHD, oncodermatologic conditions, and others
Manage complications that may arise as a result of systemic therapeutic options prescribed by the dermatologist
Discuss new understanding of pathophysiologic mechanisms that may impact adverse effects and open new treatment paradigms
DIRECTOR
Steven T. Chen, MD, MPH, FAAD
MassGeneral Brigham/Harvard Medical School
SPEAKERS
Chia-Yu Chu, MD, IFAAD
National Taiwan University
Madeline DeWane, MD, FAAD
Scott Elman, MD, FAAD
University of Miami
Michael Stephens, MD, FAAD
Mass General Brigham
DISCLOSURES
Steven T. Chen, MD, MPH, FAAD
AbbVie – Advisory Board(Honoraria); Vertex Pharmaceuticals Incorporated – Employee (w-2 relationship)(Salary); VisualDx – Independent Contractor(Fees);
Chia-Yu Chu, MD, IFAAD
No financial relationships exist with ineligible companies.
Madeline DeWane, MD, FAAD
Veradermics Inc – Stockholder Public Company(No Compensation Received);
Scott Elman, MD, FAAD
Biogen – Consultant(Fees); Blueprint Medicines – Advisory Board(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Michael Stephens, MD, FAAD
No financial relationships exist with ineligible companies.